Search Results

You are looking at 11 - 20 of 595 items for :

  • "surveillance" x
Clear All
Full access

Kathryn J. Ruddy, Lindsey Sangaralingham, Rachel A. Freedman, Sarah S. Mougalian, Heather Neuman, Caprice Greenberg, Ahmedin Jemal, Narjust Duma, Tufia C. Haddad, Valerie Lemaine, Karthik Ghosh, Tina J. Hieken, Katie Hunt, Celine Vachon, Cary P. Gross and Nilay D. Shah

Breast cancer survivors who have residual breast tissue are recommended to undergo mammographic surveillance annually. ASCO, the American Cancer Society (ACS), and NCCN recommend annual mammograms beginning at 1 year after the mammogram that led

Full access

Takashi Taketa, Kazuki Sudo, Arlene M. Correa, Roopma Wadhwa, Hironori Shiozaki, Elena Elimova, Maria-Claudia Campagna, Mariela A. Blum, Heath D. Skinner, Ritsuko U. Komaki, Jeffrey H. Lee, Manoop S. Bhutani, Brian R. Weston, David C. Rice, Stephen G. Swisher, Dipen M. Maru, Wayne L. Hofstetter and Jaffer A. Ajani

relapses are common. 7 - 10 After TMT, most patients undergo surveillance for at least 5 years; however, the surveillance recommendations vary considerably and are often empiric in nature. 6 , 10 Relapses seem to be related to the sensitivity of the

Full access

Simon D. Fung-Kee-Fung, Sima P. Porten, Maxwell V. Meng and Michael Kuettel

-risk disease. Active surveillance (AS) provides a management strategy in this group that may help identify men who truly need treatment and avoid treatment-related side effects in those who do not require intervention. 1 In 2010, NCCN incorporated AS into the

Full access

Nina D. Wagner-Johnston and Nancy L. Bartlett

imaging studies in cases of lymphoma Analyze the cost-effectiveness of imaging studies in the surveillance of patients with lymphoma Evaluate the risk for cancer associated with radiation exposure from imaging studies L arge randomized trials of

Full access

Mariela A. Blum Murphy, Takashi Taketa, Kazuki Sudo, Jeffrey H. Lee and Jaffer A. Ajani

current societies. These complexities include relatively high prevalence of the targeted condition, simplicity with which surveillance can be accomplished, low or absent complication rates, high sensitivity and specificity of the test for screening, and

Full access

Lillie D. Shockney

. From a psychosocial perspective, these survivors may experience great difficulty reclaiming their lives and moving forward. 9 Late Effects and Surveillance The survivorship care plan should also contain a description of the possible clinical

Full access

James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Christopher J. Kane, Mark H. Kawachi, Michael Kuettel, Timothy M. Kuzel, Richard J. Lee, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, David Raben, Sylvia Richey, Mack Roach III, Eric Rohren, Stan Rosenfeld, Edward Schaeffer, Eric J. Small, Guru Sonpavde, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Dorothy A. Shead and Maria Ho

disease, can be found online at NCCN.org . Estimates of Life Expectancy Estimates of life expectancy have emerged as a key determinant of primary treatment, particularly when considering active surveillance or observation. Although estimating life

Full access

Shrujal S. Baxi, Lara Dunn and David G. Pfister

The central rationale for active surveillance after curative treatment of head and neck squamous cell carcinoma (HNSCC) is the belief that earlier detection of recurrent or new primary cancers facilitates earlier initiation of therapy and can

Full access

Ayal A. Aizer, Jonathan J. Paly, Anthony L. Zietman, Paul L. Nguyen, Clair J. Beard, Sandhya K. Rao, Irving D. Kaplan, Andrzej Niemierko, Michelle S. Hirsch, Chin-Lee Wu, Aria F. Olumi, M. Dror Michaelson, Anthony V. D’Amico and Jason A. Efstathiou

active surveillance to be a standard option for all men with very-low-risk prostate cancer, and the only option for men with very-low-risk prostate cancer and an expected survival of less than 20 years. Under an active surveillance regimen, immediate

Full access

Shajan Peter

Surveillance differs from screening, and refers to the interval use of colonoscopy in patients with previously detected precancerous lesions. Surveillance accounts for 20% of the colonoscopy volume in the United States. Current, well-recognized guidelines on